ImmunityBio
Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune SystemCareers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Recent News
Apr. 1, 2020
ImmunityBio Combines Supercomputing Power with Microsoft Azure to Target Infection “Doorway” of the Coronavirus
Recent News
Apr. 1, 2020
ImmunityBio Combines Supercomputing Power with Microsoft Azure to Target Infection “Doorway” of the Coronavirus
About Us
ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
Careers
Join our fast-growing immunotherapy company. We offer you the chance to work with a team that is focused on building something impactful.
Contact Us
© 2020 ImmunityBio, Inc. All rights reserved.